Free Trial

Merck KGaA (ETR:MRK) Shares Up 0.8% - Still a Buy?

Merck KGaA logo with Medical background

Merck KGaA (ETR:MRK - Get Free Report)'s stock price traded up 0.8% during mid-day trading on Tuesday . The company traded as high as €143.10 ($150.63) and last traded at €142.95 ($150.47). 482,634 shares were traded during trading, The stock had previously closed at €141.75 ($149.21).

Merck KGaA Trading Down 0.8 %

The business has a fifty day moving average price of €154.19 and a 200-day moving average price of €160.74. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 37.56. The company has a market cap of $18.32 billion, a P/E ratio of 23.47, a PEG ratio of 2.37 and a beta of 0.71.

About Merck KGaA

(Get Free Report)

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Read More

Should you invest $1,000 in Merck KGaA right now?

Before you consider Merck KGaA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.

While Merck KGaA currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs
How Abacus Life is Transforming Life Insurance into Assets | MarketBeat CEO Series
NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines